Analgesic Efficacy and Safety Study of T-62 in Subjects With Postherpetic Neuralgia

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Postherpetic Neuralgia

In brief

The purpose of this study is to evaluate the safety and efficacy of T-62 in subjects with postherpetic neuralgia.

Key facts

Study ID

NCT00809679

Run by

Pfizer

People needed

19

Starts

2008-12-01

Expected to finish

2009-06-01

Last updated by the study team

2012-06-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Tucson, Arizona, United States
• Study site — Westlake Village, California, United States
• Study site — Bradenton, Florida, United States
• Study site — Naples, Florida, United States
• Study site — New Port Richey, Florida, United States
• Study site — Sunrise, Florida, United States
• Study site — Tampa, Florida, United States
• Study site — Lexington, Kentucky, United States
• Study site — Albuquerque, New Mexico, United States
• Study site — Winston-Salem, North Carolina, United States
• Study site — Oklahoma City, Oklahoma, United States
• Study site — San Antonio, Texas, United States
• Study site — Spokane, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.